nach oben

Drugs

Erschienen in:

01.11.2012 | Therapy In Practice

Management of Bleeding in Patients Receiving Conventional or New Anticoagulants

A Practical and Case-Based Approach

verfasst von: Marco P. Donadini, Walter Ageno, Dr James D. Douketis

Erschienen in: Drugs | Ausgabe 15/2012

Einloggen, um Zugang zu erhalten

Abstract

Anticoagulant drugs are highly effective for the prevention and treatment of venous and arterial thromboembolism. However, their use is also associated with an increased risk for bleeding, with an associated ~10% case-fatality rate. Appropriate strategies for the management and reversal of anticoagulant-associated bleeding are clinically important and, ideally, should be standardized. These include general resuscitation, and diagnosis and local treatment of the bleeding source, and one or more of the following interventions: transfusion of red cells; transfusion of clotting factor replacements; and administration of anticoagulant antidotes and other prohaemostatic agents. Reversal strategies for the ‘conventional’ anticoagulants are based largely on clinical evidence, whereas evidence to guide the management of bleeding associated with ‘new’ anticoagulants is emerging. This review provides an evidence-based, but practical, patient-focused approach for the management of bleeding associated with the old and new anticoagulants.

Warkentin AE, Donadini MP, Spencer FA, et al. Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. J Thromb Haemost 2012; 10: 512–20PubMedCrossRef

Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–4PubMedCrossRef

Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202–4PubMedCrossRef

Ost D, Tepper J, Mihara H, et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005; 294: 76–715

Palareti G, Leali N, Coccheri S, et al. Bleeding complication of anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423–8PubMedCrossRef

Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1947–8CrossRef

Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl.): e419S–94SPubMedCrossRef

Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (6 Suppl.): 257S–98SPubMedCrossRef

Carrier M, Le Gal G, Wells PS, et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152: 578–89PubMedCrossRef

10.

Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893–900PubMedCrossRef

11.

Appelboam R, Thomas EO. Warfarin and intracranial haemorrhage. Blood Rev 2009; 23: 1–9PubMedCrossRef

12.

Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl.): e44S–88SPubMedCrossRef

13.

Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl.): e152S–84SPubMedCrossRef

14.

Fiore LD, Scola MA, Cantillon CE, et al. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001; 11: 175–83PubMedCrossRef

15.

Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol 2002; 89: 400–6PubMedCrossRef

16.

White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in international normalized ratio. Ann Intern Med 1995; 122: 40–2PubMedCrossRef

17.

Contreras M, Ala FA, Greaves M, et al. Guidelines for the use of fresh frozen plasma. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force. Transfus Med 1992; 2: 57–63PubMedCrossRef

18.

O’Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11–28PubMedCrossRef

19.

Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 2007; 131: 1308–14PubMedCrossRef

20.

Lubetsky A, Hoffman R, Zimlichman R, et al. Efficacy and safety of a Prothrombin Complex Concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004; 113: 371–8PubMedCrossRef

21.

Dentali F, Marchesi C, Giorgi Piefranceschi M, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. Thromb Haemost 2011; 106:429–38PubMedCrossRef

22.

Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4: 1853–63PubMedCrossRef

23.

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–51PubMedCrossRef

24.

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–91PubMedCrossRef

25.

EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–510CrossRef

26.

EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–97CrossRef

27.

Douketis JD, Arneklev K, Goldhaber SZ, et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med 2006; 166: 853–9PubMedCrossRef

28.

Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572–85PubMedCrossRef

29.

Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1056–64PubMedCrossRef

30.

van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor. Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116–27PubMedCrossRef

31.

Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010; 70: 703–12PubMedCrossRef

32.

van Ryn J, Sieger P, Kink-Eiband M, et al. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro [abstract]. 51st ASH Annual Meeting and Exposition; 2009 Dec 7–8; New Orleans (LA)

33.

Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594–9PubMedCrossRef

34.

Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573–9PubMedCrossRef

35.

Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012 Jul 25; 108 (2): 217–24PubMedCrossRef

36.

van Ryn J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticogulation [abstract]. 53rd ASH Annual Meeting and Exposition; 2011 Dec 10–13; San Diego (CA)

37.

Tinel H, Huetter J, Perzborn E. Recombinant factor VIIA partially reverses the anticoagulant effect of high-dose rivaroxaban a novel, oral, direct factor Xa inhibitor in rats [abstract no. P-W-652]. J Thromb Haemost 2007; 5

38.

Gruber A, Marzec UM, Holcomb JB. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates [abstract]. 50th ASH Annual Meeting and Exposition; 2008 Dec 6–9; San Francisco (CA)

39.

Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259–68PubMedCrossRef

40.

Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 Suppl. 1: S141–5PubMedCrossRef

41.

Büller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867–73PubMedCrossRef

42.

Büller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695–702PubMedCrossRef

43.

Decousus H, Prandoni P, Mismetti P, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010; 363: 1222–32PubMedCrossRef

44.

Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl.): e24S–43SPubMedCrossRef

45.

Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631–6PubMedCrossRef

46.

Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011; 9 (9): 1705–12PubMedCrossRef

47.

Caplan SN, Berkman EM. Protamine sulfate and fish allergy [letter]. N Engl J Med 1976; 295 (3): 172PubMed

48.

Levi M, Eerenberg E, Lowenberg E, et al. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68: 68–76PubMed

49.

Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003; 82: 257–8PubMed

50.

Elmer J, Wittels KA. Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature. Transfus Med 2012; 22: 108–15PubMedCrossRef

51.

Desmurs-Clavel H, Huchon C, Chatard B, et al. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res 2009; 123: 796–8PubMedCrossRef

52.

Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124: 653–8PubMedCrossRef

53.

Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550–4PubMedCrossRef

54.

Bianchini EP, Fazavana J, Picard V, et al. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood 2011; 117: 2054–60PubMedCrossRef

55.

Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–92PubMedCrossRef

56.

Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–17PubMedCrossRef

57.

Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011; 9: 92–9CrossRef

58.

Paty J, Trellu M, Destors JM, et al. Reversibility of the anti-Xa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010; 8: 722–9PubMedCrossRef

59.

Büller HR, Gallus AS, Pillion G, et al. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012; 379: 123–9PubMedCrossRef

60.

Bianchini EP, Fazavana J, Picard V, et al. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood 2011 Feb 10; 117 (6): 2054–60PubMedCrossRef

61.

Lu G, Deguzman FR, Karbarz MJ, et al. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445). Eur Heart J 2011; 32 (Abstract Suppl.):640–1

Titel: Management of Bleeding in Patients Receiving Conventional or New Anticoagulants
A Practical and Case-Based Approach
verfasst von: Marco P. Donadini
Walter Ageno
Dr James D. Douketis
Publikationsdatum: 01.11.2012
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 15/2012
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11641160-000000000-00000

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Management of Bleeding in Patients Receiving Conventional or New Anticoagulants

A Practical and Case-Based Approach

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15/2012

Adjuvant Therapy for High-Risk Gastrointestinal Stromal Tumour

Carfilzomib

Phentermine and Topiramate Extended Release (Qsymia™)

Comparison of Amoxicillin/Clavulanic Acid High Dose with Cefdinir in the Treatment of Acute Otitis Media

Aclidinium

Ferumoxytol